Malignant Tumor Patients Research Articles

Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?

Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?

Second Malignant Neoplasms in Patients With Rhabdomyosarcoma.

ObjectiveRhabdomyosarcoma (RMS) is a rare malignant tumor. The main treatment modality is comprehensive with chemotherapy, radiotherapy, and surgery. With the advancement in recent decades, patient survival has been prolonged, and long-term complications are attracting increasing attention among both physicians and patients. This study aimed to present the survival of patients with RMS and analyze the risk factors for the development of a second malignant neoplasm (SMN).MethodsThe Surveillance, Epidemiology, and End Results (SEER) Program 18 registry database from 1973 to 2015 of the National Cancer Institute of the United States was used for the survival analyses, and the SEER 9 for the SMN analysis.ResultsThe 5-, 10-, and 20-year overall survival rates of the patients with RMS were 45%, 43%, and 33%, respectively. The risk of SMN was significantly higher in patients with RMS compared to the general population (SIR=1.95, 95% CI: 1.44 – 2.57, p < 0.001). The risk of developing SMN was increased in multiple locations, including the bones and joints (SIR = 35.25) soft tissues including the heart (SIR = 22.5), breasts (SIR = 2.10), male genital organs (SIR = 118.14), urinary system (SIR = 2.36), brain (SIR = 9.21), and all nervous system organs (SIR = 8.59). The multivariate analysis indicated that RMS in the limbs and earlier diagnosis time were independent risk factors for the development of SMN. Patients with head and neck (OR = 0.546, 95% CI: 0.313 – 0.952, p = 0.033) and trunk RMS (OR = 0.322, 95% CI: 0.184 – 0.564. p < 0.001) and a later diagnosis time were less likely to develop SMN (OR = 0.496, 95% CI: 0.421 – 0.585, p < 0.001).ConclusionThis study describes the risk factors associated with the development of SMN in patients with RMS, which is helpful for the personalized screening of high-risk patients with RMS.

Multi-joint steroid-induced avascular necrosis in a malignant brain tumor patient

Avascular necrosis (AVN) is a rare but serious adverse event associated with the use of corticosteroids for long durations or at high doses. This case report describes a 47-year-old female patient with low-grade astrocytoma who was initiated on low-dose dexamethasone for symptom management. The patient developed joint pain 1 year after steroid exposure, then was found to have AVN of the hip followed by multiple other joints. This case report highlights the extent to which AVN can occur in patients with brain tumors following a short course of low-dose corticosteroids. Careful evaluation of and monitoring for the development of AVN should occur frequently in patients with brain tumors given the frequent use of corticosteroids for symptom management in this population.

George Gershwin (1898-1937) - genius composer, malignant brain tumor patient. Malignant glioma: an irritating∕stimulating element in triggering geniality?

George Gershwin (1898–1937) was one of the most influential American composers of the 20th century. Likewise his swift, comet-like, career progress from a high school dropout to an iconic composer of the 20th century: “The man who said he had more notes in his head than he could write down in a hundred years died suddenly … in Hollywood”. His malignant glioma presented symptoms only in his last year of life and even then, the symptoms were masked by other hectic events in his personal life, which typical accompany the life of a famous and handsome composer from Hollywood. Considering new, emerging studies regarding the relationship between gliomas and brain activity, the authors explore the following questions: (i) Is intense neuronal, intellectual activity a cause that can trigger the development of a malignant brain tumor, especially a glioblastoma? (ii) Is glioblastoma and its connections with normal nerve cells, with noble tissue (a fact demonstrated in recent years), a cause that can trigger geniality, a different thought process from most people with a normal-functioning brain?

Second primary malignancy among malignant solid tumor survivors aged 85\xa0years and older

The cancer burden in the oldest old has increased rapidly. This study aimed to investigate the epidemiology of second primary malignancy (SPM) in malignant solid tumor survivors aged 85 years and older utilizing the Surveillance, Epidemiology, and End Results (SEER) database. A total of 128,466 malignant solid tumor patients had been identified between 2000 and 2011, including 6774 patients who developed a SPM. The overall crude incidence of developing a SPM was 5.3%. Considering death as a competing event, the 3, 5, and 10-year cumulative incidence was 1.9%, 3.2%, and 5.4%, respectively. Relative younger age, male gender, surgery history, local stage and first primary malignancy (FPM) site located in the urinary system were related to higher cumulative incidence. A median time interval of 24.0 months was found between diagnosis of FPM and SPM. The most common SPM site was digestive system, whereas the least common was oral cavity and pharynx. The median overall survival (OS) was 49.0 months, and the median survival after SPM was 13.0 months. Relative older age, male gender and black race were associated with worse OS and survival after SPM, as well as higher hazard ratios of death. In conclusions, this study performed a comprehensive analysis of SPM among malignant solid tumor survivors aged 85 years and older. Additional studies are needed to characterize the specific cancer type of interest.

County-based demographics, patterns of treatment seeking, and disease burden for malignant tumor patients in China.

The mortality of malignant tumors in rural areas of China in 2015 was significantly higher than that in city areas (213.6 per 100,000 vs. 191.5 per 100,000), bringing huge economic pressure to individuals and the local community. The comprehensive reform of county-level public hospitals in Yun County has helped patients with critical disease receive appropriate treatment. Therefore, an analysis focused on the epidemiology and disease burden of malignant tumors in Yun County could provide guidance for administrators and health practitioners in other counties. This retrospective database study extracted data from the Yun County medical community (including two higher level hospitals: Yun County People's Hospital and Yun County Chinese Medicine Hospital, and 13 township central hospitals) from 1st Jul 2017 to 30th Aug 2020. Patients diagnosed as having a malignant tumor were enrolled and those with abnormal key baseline information were excluded. The epidemiology and disease burden for malignant tumor patients were assessed. A total of 3,792 patients were enrolled, and the most prevalent cancer in 2018 was thyroid (35.4 patients/100,000) and in 2019 this was lung cancer (30.6 patients/100,000). The mean outpatient visits per person for all-cause and tumor-specific visits were 9.99 and 3.94 visits across 2018 and 2019, respectively, and the mean inpatient visits per person in both years were the same at 2.56 visits. Total costs were 14.471 and 20.29 million in 2018 and 2019, respectively, and 71.7% and 73.0% of the total cost were covered by medical insurance over the 2 years. The medical environment has improved since medical system reform commenced in 2019 in Yun County, and medical insurance has decreased the disease burden for patients and their families significantly.

Region-Growing Algorithm on CT Angiography Images for Detection of Gynecological Malignant Tumor

This paper aimed to explore pelvic lymphadenectomy for gynecological malignant tumors guided by computed tomography angiography (CTA) images under region-growing algorithm (RGA). 100 cases of malignant tumor patients who received pelvic lymphadenectomy in hospital from January 2018 to January 2020 were analyzed. Patients were classified into control group (CTA image) and experimental group (RGA-based CTA image), each with 50 cases. The overall accuracy (OA) of the pelvic CT image segmentation parameters under RGA, the watershed segmentation algorithm (WA), and the swarm intelligence optimization algorithm (SIOA) was compared. Comparisons of segmentation parameters, denoising performance, and CT imaging of patients as well as diagnosis rate and total efficiency rate were carried out. The results showed that overall accuracy (OA) of RGA was considerably higher versus watershed segmentation algorithm (WA) and swarm intelligence optimization algorithm (SIOA). However, false positive rate (FPR) and false negative rate (FNR) of RGA were greatly lower than those of other algorithms. RGA greatly improved the accuracy of pelvic tumor detection. The peak signal-to-noise ratio (PSNR) of RGA was superior to that of WA and SIOA, but differences in edge preservation index (EPI) value were not significant. The diagnosis rate of the experimental group was 48/50 (96%), while the diagnosis rate by manual means was 38/50 (76%). For the diagnosis rate and total efficiency, results of the experimental group were evidently higher in contrast to the control group ( P &lt; 0.05 ). In conclusion, under RGA, CTA image-guided pelvic lymphadenectomy had good segmentation accuracy and denoising performance, and it was superior in total efficiency and diagnosis rate, which was worthy of clinical promotion.

Copper content in ascitic fluid is associated with angiogenesis and progression in ovarian cancer

BackgroundAscites is associated with the poor prognosis of malignant tumors. The biological importance of the changes in the content of trace elements in the ascitic fluid is unknown. Herein, we analyzed trace elements in the ascitic fluid of patients with ovarian tumors and used cultured cells to determine the copper (Cu)-induced changes in gene expression in ovarian cancer. MethodsInductively coupled plasma mass spectrometry (ICP-MS) was used to compare ascitic fluid trace element levels in patients with benign ovarian tumors (n = 22) and borderline/malignant tumors (n = 5) for primary screening. Cu levels were validated using atomic absorption spectrometry (AAS) in 88 benign, 11 borderline, and 25 malignant ovarian tumor patients. To confirm Cu-induced gene expression changes, microarray analysis was performed for Cu-treated OVCAR3, A2780, and Met5A cells. The vascular endothelial growth factor (VEGF) concentration in the cell supernatant or ascitic fluid (ovarian cancer samples) was measured using ELISA. ResultsICP-MS showed that Co, Ni, Cu, Zn, As, Se, and Mo levels significantly increased in patients with malignant/borderline ovarian tumors compared to those in patients with benign ovarian tumors. AAS showed that malignant ovarian tumors were independently associated with elevated levels of Cu in ascites adjusted for age, body mass index, alcohol, smoking, and supplement use (p < 0.001). Microarray analysis of both Cu-treated ovarian cancer cell lines OVCAR3 and A2780 and the mesothelial cell line Met-5A revealed the upregulation of the angiogenesis biological process. Real-time polymerase chain reaction and ELISA demonstrated that an increased Cu content significantly enhanced VEGF mRNA expression and protein secretion in OVCAR3, A2780, and Met-5A cells. VEGF levels and clinical stages of the tumors correlated with the ascitic fluid Cu content in patients with malignant ovarian tumors (correlation coefficient 0.445, 95 % confidence interval [CI]: 0.069–0.710, p = 0.023 and correlation coefficient 0.406, 95 % CI: 0.022–0.686, p = 0.040, respectively). ConclusionCu levels significantly increased in patients with malignant ovarian cancer. Cu induced angiogenic effects in ovarian cancer and mesothelial cells, which affected ascites fluid production. This study clarifies the link between elevated Cu in ascites and malignant ovarian tumor progression. Strategies to decrease Cu levels in the ascitic fluid may help downregulate VEGF expression, thereby improving the prognosis of ovarian malignancies.

100 TOTAL LYMPHOCYTES COUNT (TLC) PREDICTS THE OVERALL SURVIVAL AFTER CHEMORADIOTHERAPY IN ESOPHAGEAL CARCINOMA PATIENTS

Abstract Lymphocytes play a critical role in the host immune system, and a decrease in number of lymphocytes, caused by malnutritional status and chemoradiotherapy (CRT) leads to immunosuppression. Immunosuppression could enhance the cancer development and progression. Previous studies demonstrated that lymphopenia was associated with worse prognosis in the pancreatic, lung, head and neck, and rectal cancer, but little is known about esophageal cancer. Methods There were 298 patients of esophageal malignant tumors, who had been initially treated with chemoradiotherapy (CRT) between January, 2007 and December, 2018. The total lymphocyte counts (TLC) before CRT and the nadir value during 6 weeks after CRT along with other clinical and treatment characteristics of these 298 patients, were retrospectively evaluated in relevance with the overall survival (OS) after CRT. Results The median TLC before and after CRT were 1469 (range 456–4710)/mm3 and 354 (range 21–1500)/mm3, respectively. When the patients were stratified with the threshold value of 1500/mm3 of pretreatment TLC, the Log-Rank test showed significant difference in OS between these 2 groups (OS 48.7% vs 36.6%, p = 0.011). In addition, the CTCAE grade of lymphopenia exceeding 3 after CRT was associated with worse OS even in the group with pretreatment TLC level more than 1500/mm3. The multivariate analysis showed that the significant prognostic factors of OS were cN, cM, additional esophagectomy and pretreatment TLC. Conclusion The decease of pretreatment TLC was significantly associated with worse OS when the patients of esophageal cancer were initially treated with CRT.

Detection of Neoplasms by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid

Cerebrospinal fluid (CSF) cytologic testing and flow cytometry are insensitive for diagnosing neoplasms of the central nervous system (CNS). Such clinical phenotypes can mimic infectious and autoimmune causes of meningoencephalitis. To ascertain whether CSF metagenomic next-generation sequencing (mNGS) can identify aneuploidy, a hallmark of malignant neoplasms, in difficult-to-diagnose cases of CNS malignant neoplasm. Two case-control studies were performed at the University of California, San Francisco (UCSF). The first study used CSF specimens collected at the UCSF Clinical Laboratories between July 1, 2017, and December 31, 2019, and evaluated test performance in specimens from patients with a CNS malignant neoplasm (positive controls) or without (negative controls). The results were compared with those from CSF cytologic testing and/or flow cytometry. The second study evaluated patients who were enrolled in an ongoing prospective study between April 1, 2014, and July 31, 2019, with presentations that were suggestive of neuroinflammatory disease but who were ultimately diagnosed with a CNS malignant neoplasm. Cases of individuals whose tumors could have been detected earlier without additional invasive testing are discussed. The primary outcome measures were the sensitivity and specificity of aneuploidy detection by CSF mNGS. Secondary subset analyses included a comparison of CSF and tumor tissue chromosomal abnormalities and the identification of neuroimaging characteristics that were associated with test performance. Across both studies, 130 participants were included (median [interquartile range] age, 57.5 [43.3-68.0] years; 72 men [55.4%]). The test performance study used 125 residual laboratory CSF specimens from 47 patients with a CNS malignant neoplasm and 56 patients with other neurological diseases. The neuroinflammatory disease study enrolled 12 patients and 17 matched control participants. The sensitivity of the CSF mNGS assay was 75% (95% CI, 63%-85%), and the specificity was 100% (95% CI, 96%-100%). Aneuploidy was detected in 64% (95% CI, 41%-83%) of the patients in the test performance study with nondiagnostic cytologic testing and/or flow cytometry, and in 55% (95% CI, 23%-83%) of patients in the neuroinflammatory disease study who were ultimately diagnosed with a CNS malignant neoplasm. Of the patients in whom aneuploidy was detected, 38 (90.5%) had multiple copy number variations with tumor fractions ranging from 31% to 49%. This case-control study showed that CSF mNGS, which has low specimen volume requirements, does not require the preservation of cell integrity, and was orginally developed to diagnose neurologic infections, can also detect genetic evidence of a CNS malignant neoplasm in patients in whom CSF cytologic testing and/or flow cytometry yielded negative results with a low risk of false-positive results.

Incidence of Benign and Malignant Tumors in Patients With Acromegaly Is Increased: A Nationwide Population-based Study.

Whether cancer risk in acromegaly is increased remains controversial, and the risk of benign tumors has been little studied. To investigate the incidence of benign and malignant tumors in acromegaly in a nationwide population-based study. Adult patients diagnosed with acromegaly between 1987 and 2017 were identified in the Swedish National Patient Registry. The diagnoses of benign and malignant tumors were recorded. Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) for neoplasms with 95% CIs were calculated using the Swedish general population as reference. The study included 1296 patients (52% women). Mean (SD) age at diagnosis was 51.6 (14.7) years. Median (range) follow-up time was 11.7 (0-31) years. Overall, 186 malignancies were identified in acromegalic patients compared with 144 expected in the general population (SIR 1.3; 95% CI 1.1-1.5). The incidence of colorectal and anal cancer (SIR 1.5; 95% CI 1.0-2.2), and renal and ureteral cancer (SIR 4.0; 95% CI 2.3-6.5) was increased, whereas the incidence of malignancies of the respiratory system, brain, prostate, and breast was not. Only 3 cases of thyroid cancer were recorded. Mortality due to malignancies was not increased (SMR 1.1; 95% CI 0.9-1.4). Incidence of benign tumors was increased more than 2-fold (SIR 2.4; 95% CI 2.1-2.7). Patients with acromegaly had an increased risk of both benign and malignant tumors, including colorectal and anal cancer, and renal and ureteral cancer. Whether this is associated with acromegaly itself or due to more intensive medical surveillance remains to be shown.

New Approaches to the Surgical Treatment of Lung and Bronchial Tumors in Children

Today, it is relevant to search for new, better methods of surgical treatment of tumors and organ-preserving and video-assisted surgery is gaining more and more popularity. The aim of the study was to improve the results of surgical treatment of children with primary and secondary (metastatic) lung tumors using high-frequency live tissue welding (HF LTW) in order to increase the treatment effectiveness. Novelty of the study lies in the expanding the knowledge of the new researched method, for enhancement of survivability relatively to chemotherapy and radiation methods, that are studied in the previous works. Advantages of the introduced method are bloodless, fast, low traumatic operations 103 case reports in children with primary and metastatic lung tumors were analyzed, including 34 patients with benign and malignant lung tumors and 69 children with metastatic bronchial and pulmonary lesions undergoing treatment from 2002 to 2018 were examined. Benign lung tumors were diagnosed in 17 patients. Malignant tumors were observed in 17 patients, including 11 lung carcinoid tumors. Metastatic bronchial and pulmonary lesions most often occurred with osteosarcoma (28) and nephroblastoma (17). In 34 children with primary tumors, 37 were undergone surgical interventions. Most often, atypical resection was used – 16 (43.3%), in particular, with carcinoid – in 7 (43.8%) patients and with hamartoma – in 4 (25%) patients. In metastatic lesions, in most cases, the same resection was performed. From 58 resections 25 (43%) were performed for osteosarcoma and 15 (26%) for nephroblastoma. The HF LTW method was used in 29 patients for benign and malignant primary tumors and in 62 (73%) surgical procedures for lung metastases to remove a tumor, vascular coagulation and sealing of the lung tissue. Using HF LTW surgical operations of different directions and volumes can be performed effectively in benign, malignant and metastatic bronchial and pulmonary lesions in children.

The Clinical Characteristics and CT Findings of Parotid and Submandibular Gland Tumours.

Objective To investigate the clinical characteristics and CT findings of parotid and submandibular gland tumours. Materials and methods. From May 2017 to April 2020, all patients with clinically proven parotid and submandibular gland enlargement and palpable masses underwent CT examinations. All patients were confirmed by pathology after surgery. The clinical characteristics and CT features were observed and evaluated. The mean density values before and after enhancement were measured and analyzed. The chi-square test, one-way ANOVA, and Student's t-test were used. Results Ninety-four patients with a total of 94 unilateral tumours in the parotid and submandibular glands were enrolled, including 38 pleomorphic adenomas (PAs), 27 Warthin's tumours (WTs), and 29 malignant tumours (MTs). The majority of the PAs (28/38) and MTs (23/29) were located in the parotid gland; the others were located in the submandibular gland. All the WTs were in the parotid gland. The most common benign tumours of the parotid gland were PAs (28/38, 73.7%) and WTs (27/27, 100%), and the most common MTs were mucoepidermoid carcinoma, acinic cell carcinoma, and squamous cell carcinoma (4/29, 13.8%). The most common benign and malignant tumours in the submandibular gland were PAs (10/38, 26.3%) and ductal adenocarcinomas (3/4, 75%). The majority of PA patients (28/38) were female, compared with WT (2/27) (P < 0.001) and malignant tumour patients (10/29) (P < 0.01). A significant difference was also found between WTs and MTs in female patients (P < 0.05). The mean age of PA patients was 43.4 ± 12.1 years, which was lower than that of WTs (62.1 ± 11.7) and MTs (58 ± 14.18) (P < 0.001, P < 0.001, and P=0.244, respectively). On CT imaging, the mean diameter of the PAs and WTs was significantly smaller than that of the MTs (P=0.001 and P < 0.001), and no difference was observed between the PAs and WTs (P=0.275). In the parotid gland, the superficial lobe was more frequently involved than the deep lobe (PAs, 22 : 6; WTs, 17 : 10; and MTs, 15 : 8). The majority of PAs and WTs demonstrated round shapes (25/38, 19/27) and were well defined (30/38, 24/27); by contrast, most MTs were lobulated, irregular shapes (24/29), and ill defined (25/29). On plain CT, the PAs were usually homogeneous, while MTs were frequently heterogeneous, with more necrosis, larger cystic areas, and more haemorrhage or calcification. The mean CT values of PAs, WTs, and MTs were 39.2 ± 3.9 HU, 39.1 ± 3.0 HU, and 37.6 ± 3.1 HU (P > 0.05), respectively. On contrast CT, the WTs were significantly enhanced compared with MTs and PAs, with mean CT values of 53.5 ± 4.0 HU, 84.4 ± 6.0 HU, and 65.2 ± 3.8 HU, respectively (all P < 0.001). The mean CT value changes for PAs, WTs, and MTs (∆) were 14.4 ± 3.0 HU, 45.3 ± 4.5 HU, and 27.7 ± 2.5 HU, respectively. Significant differences were observed between ∆PAs and ∆WTs, ∆PAs and ∆MTs, and ∆WTs and ∆MTs (all P < 0.001). Conclusion Parotid and submandibular gland tumours have some typical clinical characteristics and CT findings, and plain and early contrast-phase CT combined with clinical parameters may be helpful for diagnosis.

Risk factors for oral mucositis in patients with malignant tumors: a prospective cohort study.

To investigate the incidence and risk factors of oral mucositis in patients with malignant tumors. A total of 74 patients with malignant tumors who were hospitalized in the Affiliated Hospital of Nantong University from January 2020 to December 2020 were selected and divided into two groups according to whether oral mucositis occurred (n=45) or not (n=29). Chi-square test was used to compare the general data between the two groups, and multivariate logistic regression analysis was used to investigate the risk factors of oral mucositis in patients with malignant tumors. Oral mucositis occurred in 45 of 74 malignant tumor patients (60.8%), and the incidence in patients with head and neck tumors was significantly higher than in those with chest and abdomen tumors (P<0.05). A significantly higher incidence was also seen in patients with poor oral cleanliness in comparison to those with high oral cleanliness; in radiotherapy patients in comparison to non-radiotherapy patients; in patients who received Nituzumab during radiotherapy in comparison to those who did not, and in patients receiving eight cycles of chemotherapy in comparison to those not receiving chemotherapy. Multivariate logistic regression analysis showed that oral cleanliness, radiotherapy, and duration of radiotherapy were independent risk factors for oral mucositis in patients with malignant tumors (P<0.05). Poor oral cleanliness, radiotherapy, and longer duration of radiotherapy lead to the occurrence of oral mucositis in patients with malignant tumors, and these risk factors should be targeted for intervention to reduce the occurrence of oral mucositis.

Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.

Background Nowadays, PD-1/PD-L1 inhibitors are widely used to treat various malignant tumors. However, during the immunotherapy in a few patients, a flare-up of tumor growth occurred. This new pattern of progression is called hyperprogressive disease (HPD). Patients and Methods. The retrospective study included 377 patients with various malignant tumors treated with PD-1 inhibitors (nivolumab or pembrolizumab) in the Chinese PLA General Hospital from January 2015 to January 2019. Clinicopathologic variables, tumor growth rate (TGR), and treatment outcomes were analyzed in patients with pan-cancer treated with PD-1 inhibitors. HPD was defined as the difference of TGR before and during immunotherapy exceeding 50%. Results In 38 of 377 patients (10.08%), HPD occurred after treatment with PD-1 inhibitors. Patients with HPD had lower overall survival (OS) than those without HPD (median OS, 3.6months (95% CI, 3.0–4.2) vs. 7.3 months (95% CI, 5.9–8.7); P < 0.01). Factors related to HPD include more than 2 metastatic sites, ECOG performance status ≥ 2, hepatic metastases, and lactate dehydrogenase level greater than normal upper limit. KRAS status was significantly associated with HPD in patients with colorectal cancer. In the exploratory predictors' analysis, the rapid increase of characteristic tumor markers (such as CEA in colorectal cancer, CA199 in pancreatic cancer and cholangiocarcinoma) within one month was found to be associated with the occurrence of HPD. Conclusions HPD was developed with different rates in a variety of malignant tumor patients treated with PD-1 inhibitors and related to some clinicopathological features and poor prognosis. Tumor markers, especially CA199, might be served as early predictors of HPD.

Obstructive sleep apnea and incidence of malignant tumors: a meta-analysis

ObjectivesThis paper assessed the connection between obstructive sleep apnea (OSA) and the incidence of malignant tumors. MethodsPubMed, Cochrane, Scopus, Health Source Nursing Academic Edition, EMBASE, and Web of Sciences were searched until the date of July 25, 2020. The analysis included an assessment of the overall incidence of OSA malignancies, the incidence of OSA malignancies by age and gender, and the incidence of different types of malignancies in patients with OSA. The total rate and the corresponding 95% confidence interval (CI) of the incidence of malignant tumors in patients with OSA were calculated. Patients with OSA were classified according to age, gender, and different types of malignant tumors for meta-analysis. ResultsA total of 12 studies involving 862,820 participants were included in this meta-analysis. Random effect model analysis showed that the total incidence of malignant tumors in patients with OSA was 0.046% (95% CI: 0.027–0.065, P < 0.001), higher than that of malignant tumors in the general population. According to the analytical results classified by gender, the incidence of malignant tumor in female patients with OSA was 4.0% (95% CI: 0.014–0.066), higher than that in male patients at 3.5% (95% CI: 0.012–0.058). The analytical results classified by age showed that the incidence of malignant tumors in patients with OSA aged below 60 years was 1.8% (95% CI: 0.000–0.036), lower than that in patients aged above 60 years at 4.3% (95% CI: 0.002–0.084). The analytical results classified by the types of malignant tumors showed that the incidences of breast cancer, lung cancer, colorectal cancer, prostate cancer, kidney cancer, pancreatic cancer, and melanoma in patients with OSA were 0.5% (95% CI: 0.001–0.008), 0.5% (95% CI: 0.002–0.009), 0.5% (95% CI: 0.003–0.008), 1.1% (95% CI: 0.002–0.021), 0.3% (95% CI: 0.001–0.005), 0.1% (95% CI: 0.001–0.002), and 0.4% (95% CI: 0.003–0.005), respectively. Among them, the incidence of prostate cancer was the highest, followed by breast cancer, lung cancer, colorectal cancer, melanoma, and kidney cancer, whereas the incidence of pancreatic cancer was the lowest. However, the incidence of specific malignant tumors in patients with OSA did not have a significant increase compared with that in the general population. ConclusionsThe analytical results of this meta-analysis suggested that OSA may be associated with an overall increase in the incidence of malignancies based on the currently available data, but the connection with specific types of malignancies was not significant. Further studies are needed to explore this association in the future.

Peutz-Jeghers syndrome: what has been known for 125 years of research? (review)

Peutz-Jeghers syndrome (PJS) is an extremely rare autosomal dominant hereditary disease characterized by the growth of hamartomatous polyps in the gastrointestinal tract, mucocutaneous pigmented macules and an increased risk of malignant neoplasms of various localizations. In most cases the development of PJS is associated with the presence of a mutation in the STK11 gene, but not all patients have this mutation. This review presents the historical aspects of the first data on PJS, considers the clinical manifestations of the disease, current diagnostic methods, as well as recent knowledge about the genetic causes, about the risk of malignant neoplasms in patients with PJS, existing guidelines for screening and treatment of patients with PJS. However, the presence of a number of unresolved issues in genetics, monitoring and treatment indicates the need for further research.

Role of MRI diffusion in differentiation between benign and malignant parotid gland tumors

ROLE OF MRI DIFFUSION IN DIFFERENTIATION BETWEEN BENIGN AND MALIGNANT PAROTID GLAND TUMORS Abstract Background:The potential additional value of diffusion in oncological imaging lies in the fact that it provides functional tissue information, which can be combined with anatomical MR images to improve the specificity of lesion characterization.The DWI studies and ADC measurements provide useful information about tumor cellularity that can correlate with the histological pattern of parotid lesion and give a clue in differentiation between benign and malignant tumors Aim of work:this work aims to study the value of the diffusion weighted imaging and ADC measurement coupled with a high-resolution MR imaging technique that can enable effective characterization of histologic features of the parotid tumors. We also expected that mapping of the ADC could differentiate benign from malignant tumorsPatients and methods: This study included 25 (14female and11 male) . Patients ages ranged from 3–69 year old . All the patients presented to the National Cancer Institute during the past year. Results: combining DWI and ADC values has increased accuracy, as the sensitivity and specificity were 92.86%, 90.91% respectively with 92.86% positive predictive value and 90.91% negative predicative valueConclusion: our date and in agreement with previous studies had demonstrated that determining whether a parotid gland tumor is benign or malignant on the basis of combining morphologic features and DWIs & ADC measurements in a diagnostic noninvasive approach are very promising and might decrease number of unnecessary invasive procedures Keywords: MRI diffusion, ADC , parotid tumors

An analysis of the diagnosis, clinical characteristics, treatment, and survival outcomes of 36 extracranial malignant rhabdoid tumor patients.

BackgroundExtracranial malignant Rhabdoid tumors (eMRTs) are rare but aggressive lesions in young children. This work aimed to review and analyze the diagnosis, clinical characteristics, treatment, and survival of eMRTs so as to summarize experience for future therapy.MethodsA total of 36 eMRT cases were treated between January 2008 and August 2019 according to Shanghai Children’s Medical Center (SCMC) multimodal protocol of mixed surgery, radiation and chemotherapy involving vincristine, carboplatin, doxorubicin, etoposide, cyclophosphamide and ifosfamide. We collected information including: age at diagnosis, tumor location, disease stage, therapy, outcomes, etc. Overall survival (OS) and event free survival (EFS) were calculated and risk factors for survival were analyzed.ResultsThe patients had a median age of 1.80 years at diagnosis (range, 1.4 m–13.42 years), and were followed up for 9.17 months in median (range, 4 d–11.14 y). A total of 16 patients achieved complete remission (CR), and 7 survived without reoccurrence till December 2019. The 3-year EFS was 17.4% (95% CI: 11.0–23.8%) with a 3-year OS of 23.4% (95% CI: 15.8–31.0%). Recurrence was found only in children younger than the median age (1.80 y). Localized staging (Log Rank P=0.039 for OS and P=0.021) and older age (Log Rank P=0.016 for OS and P=0.002 for EFS) were associated with improved outcome. Younger age (Cox regression, OS, OR =2.610, 95% CI: 1.147–5.937, P=0.022; EFS, OR =3.401, 95% CI: 1.495–7.752, P=0.004) were independent risk factors for death and recurrence.ConclusionsThose eMRTs treated according to SCMC protocol turned out to have poor outcomes. Higher staging at diagnosis and reoccurrence in younger patients remain major threats to the prognosis.

Straightplasty, a Limb Salvage Procedure in Malignant and Aggressive Bone Tumors of Lower Extremities: A Retrospective Analysis.

IntroductionThe management of malignant bone tumors of lower extremities involves various modalities, which depend not only on local and systemic affection but are also affected by psychosocial factors. The purpose of this study was to evaluate functional and psychosocial outcomes in patients with non-salvageable lower limbs having malignant or aggressive benign bone tumors of distal thighs, who were treated with a technique called straightplasty.Material and methodsWe enrolled 20 patients of non-salvageable primary malignant or aggressive benign bone tumors around the knee. Out of these, 15 patients were followed and evaluated in view of functional and clinical outcomes having a minimum of 22 months of final follow-up.ResultsA total of 15 patients (8 males, 7 females) having a non-salvageable lower limb with a mean age of 20.53 years (range, 12 to 45 years), who were managed with straightplasty and followed for a mean duration of 31.73 months (range 22 to 72 months) were evaluated clinico-radiologically, and the functional outcomes were measured by Enneking’ s method. The surgical procedure is simple and better in terms of functional outcomes than other procedures described in the literature, while it is observed as psychosocially more acceptable in developing nations, especially in the Indian context. Most of the parameters are comparable to rotationplasty and above-knee amputation, whereas it is less technically demanding and satisfying due to the straight limb rather than the rotated leg in rotationplasty.ConclusionWe recommend straightplasty as an alternative to rotationplasty or above-knee amputation in patients having malignant or aggressive benign tumors around the knee joint and where limb salvage procedures are not feasible.